| Tina T James, MD | |
|
304 Church St, Sweetwater, TN 37874-1181 | |
| (865) 213-8200 | |
| Not Available |
| Full Name | Tina T James |
|---|---|
| Gender | Female |
| Speciality | Diagnostic Radiology |
| Experience | 31 Years |
| Location | 304 Church St, Sweetwater, Tennessee |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316924038 | NPI | - | NPPES |
| 3883037 | Medicaid | TN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 36120 (Tennessee) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sweetwater Hospital Association | Sweetwater, TN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Tennessee Valley Radiology Llc | 9133105521 | 33 |
News Archive
Researchers working with adult mice have discovered that learning and memory were profoundly affected when they altered the amounts of a certain protein in specific parts of the mammals' brains.
Democrats may be feeling smug about their campaign against the House Republican budget plan, and as a matter of politics, they're no doubt right. If the goal is to deal with the long-term fiscal challenge, though, the Democrats' political success is apt only to prolong the gridlock and make the eventual solution that much more painful. ...
Repros Therapeutics Inc. today announced it has received written confirmation from the FDA noting the full clinical hold on Proellex® has been lifted. The Company will be allowed to run a single study under the new partial clinical hold status. The new low dose study is designed to explore both safety and signals of efficacy in an escalating dose fashion.
A new analysis has found that a type of radiation therapy called carbon ion radiotherapy can control cancer growth and prolong survival in patients with spinal tumors. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study indicates that the treatment is a promising alternative for patients whose spinal tumors cannot be surgically removed.
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc. today announced that the company received a complete response letter from the United States (U.S.) Food and Drug Administration (FDA) regarding New Drug Applications (NDAs) for alogliptin and fixed-dose combination (FDC) alogliptin and pioglitazone.
› Verified 7 days ago
| Entity Name | Tennessee Valley Radiology Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356367551 PECOS PAC ID: 9133105521 Enrollment ID: O20040626000132 |
News Archive
Researchers working with adult mice have discovered that learning and memory were profoundly affected when they altered the amounts of a certain protein in specific parts of the mammals' brains.
Democrats may be feeling smug about their campaign against the House Republican budget plan, and as a matter of politics, they're no doubt right. If the goal is to deal with the long-term fiscal challenge, though, the Democrats' political success is apt only to prolong the gridlock and make the eventual solution that much more painful. ...
Repros Therapeutics Inc. today announced it has received written confirmation from the FDA noting the full clinical hold on Proellex® has been lifted. The Company will be allowed to run a single study under the new partial clinical hold status. The new low dose study is designed to explore both safety and signals of efficacy in an escalating dose fashion.
A new analysis has found that a type of radiation therapy called carbon ion radiotherapy can control cancer growth and prolong survival in patients with spinal tumors. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study indicates that the treatment is a promising alternative for patients whose spinal tumors cannot be surgically removed.
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc. today announced that the company received a complete response letter from the United States (U.S.) Food and Drug Administration (FDA) regarding New Drug Applications (NDAs) for alogliptin and fixed-dose combination (FDC) alogliptin and pioglitazone.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Tina T James, MD Po Box 11046, Knoxville, TN 37939-1046 Ph: (865) 320-9707 | Tina T James, MD 304 Church St, Sweetwater, TN 37874-1181 Ph: (865) 213-8200 |
News Archive
Researchers working with adult mice have discovered that learning and memory were profoundly affected when they altered the amounts of a certain protein in specific parts of the mammals' brains.
Democrats may be feeling smug about their campaign against the House Republican budget plan, and as a matter of politics, they're no doubt right. If the goal is to deal with the long-term fiscal challenge, though, the Democrats' political success is apt only to prolong the gridlock and make the eventual solution that much more painful. ...
Repros Therapeutics Inc. today announced it has received written confirmation from the FDA noting the full clinical hold on Proellex® has been lifted. The Company will be allowed to run a single study under the new partial clinical hold status. The new low dose study is designed to explore both safety and signals of efficacy in an escalating dose fashion.
A new analysis has found that a type of radiation therapy called carbon ion radiotherapy can control cancer growth and prolong survival in patients with spinal tumors. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study indicates that the treatment is a promising alternative for patients whose spinal tumors cannot be surgically removed.
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc. today announced that the company received a complete response letter from the United States (U.S.) Food and Drug Administration (FDA) regarding New Drug Applications (NDAs) for alogliptin and fixed-dose combination (FDC) alogliptin and pioglitazone.
› Verified 7 days ago
Dr. Lynda K Rogers, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 304 Church St, Sweetwater, TN 37874 Phone: 865-213-8200 | |
Dr. Bernadette King, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 304 Church St, Sweetwater, TN 37874 Phone: 865-213-8200 | |
David M Norris, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 304 Church St, Sweetwater, TN 37874 Phone: 865-213-8200 |